Wegovy Pill vs Injection Cost: UK Price Comparison Guide

Wegovy pill vs injection cost is one of the most common questions among UK adults considering private semaglutide treatment. Both formulations contain the same active ingredient but differ in dose schedule, administration method and, often, monthly price. The pill is not automatically cheaper than the injection — private UK prices overlap considerably depending on the provider, dose stage and any promotions applied. This article breaks down current broad market price ranges for each formulation, explains how costs change as doses escalate, estimates realistic first-year totals, and outlines what to consider before switching between the two.

Wegovy Pill vs Injection Cost: Which Is Cheaper in the UK?

Neither the Wegovy pill nor the injection is consistently cheaper in the UK — private prices overlap broadly, ranging from approximately £70–£200 per month for the pill and £75–£300 or more for the injection, depending on dose and provider.

When comparing Wegovy pill vs injection cost in the UK, there is no universal answer that applies to every patient or pharmacy. The Wegovy pill can be cheaper at some providers and treatment stages, while at others the oral and injectable versions are priced similarly. The amount paid privately depends on the dose, provider, introductory offers, subscriptions and what is included in the service.

As a broad guide, current private UK prices may fall into ranges such as:

• Wegovy pill: approximately £70–£200 or more per month

• Wegovy injection: approximately £75–£300 or more per month

These are deliberately broad market ranges rather than fixed national prices. The lowest figures may depend on introductory promotions or subscription conditions, while the highest injection prices are more likely to apply to higher doses or more expensive providers.

For many patients, a more useful comparison is by treatment stage:

• Lower-dose Wegovy pills may start from roughly £70–£100 per month, although some providers charge around £100–£120.

• Lower-dose Wegovy injections may start from roughly £75–£150 per month, depending heavily on the provider.

• The 25 mg Wegovy pill may cost roughly £180–£200 or more per month at some providers.

• The standard 2.4 mg Wegovy injection maintenance dose may cost roughly £175–£300 or more per month, although some pharmacies price it around the same level as the 25 mg pill.

This means the pill is not automatically cheaper simply because it is a tablet. At some providers, equivalent treatment stages are priced almost identically. At others, the tablet may offer a lower monthly cost, particularly compared with more expensive private injection services.

The comparison has become more complex because current UK prescribing information also includes a 7.2 mg once-weekly injection option for some adults with obesity where needed, after treatment at 2.4 mg. Higher-dose injectable treatment can cost more than the standard 2.4 mg maintenance dose, so a patient using 7.2 mg may face a different cost comparison from someone using a lower injection strength.

The pill and injection contain the same active ingredient, semaglutide, but they use different dose schedules and methods of administration.^[1][2] The oral treatment is taken once daily and progresses through 1.5 mg, 4 mg, 9 mg and 25 mg strengths. The standard injection schedule is once weekly and progresses through 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg.

Because the formulations are absorbed differently, the milligram numbers should not be directly compared. A 25 mg tablet is not simply more medicine than a 2.4 mg injection in a way that predicts either effectiveness or value for money.

The most accurate answer is therefore that Wegovy pills may be cheaper than injections in some circumstances, but patients need to compare the actual prescribed dose and ongoing provider price rather than assuming one formulation always costs less.

How the Monthly Cost Changes as the Wegovy Dose Increases

Both Wegovy formulations escalate through several dose levels, so the starting price is rarely representative of ongoing costs — pill prices may rise from around £70 to over £180 per month, while injection prices can rise from around £75 to over £300 per month at maintenance.

One reason the cost of Wegovy pills and injections can be difficult to compare is that both treatments use gradual dose escalation. A low starting price may have little relevance to what a patient pays later in treatment.

The standard Wegovy pill schedule is:

• Month 1: 1.5 mg once daily

• Month 2: 4 mg once daily

• Month 3: 9 mg once daily

• Month 4 onward: 25 mg once daily as the standard maintenance dose

There must be at least one month at each dose level. If needed, treatment can remain at the previous dose level under the prescribed plan.

A broad illustration of private pill pricing might be:

• 1.5 mg: approximately £70–£110 per month

• 4 mg: approximately £90–£125 per month

• 9 mg: approximately £115–£145 per month

• 25 mg: approximately £180–£200 or more per month

The standard injection schedule takes longer to reach maintenance:

• Weeks 1–4: 0.25 mg once weekly

• Weeks 5–8: 0.5 mg once weekly

• Weeks 9–12: 1 mg once weekly

• Weeks 13–16: 1.7 mg once weekly

• From week 17: 2.4 mg once weekly as the standard maintenance dose

Private injection pricing varies particularly widely. Broad market examples may fall around:

• 0.25 mg: approximately £75–£150 per month

• 0.5 mg: approximately £90–£170 per month

• 1 mg: approximately £105–£200 per month

• 1.7 mg: approximately £135–£250 per month

• 2.4 mg: approximately £175–£300 or more per month

These ranges overlap significantly. This is important. It means there is no clean dividing line where every pill price is lower than every injection price.

A patient could find a competitively priced injection provider charging less than another pharmacy charges for oral treatment. Conversely, someone paying at the upper end of the private injection market might save substantially by moving to a competitively priced pill service, if switching is clinically appropriate.

The first-year cost can therefore differ even when two providers advertise similar starting prices. The pill normally reaches its standard 25 mg maintenance stage sooner in the escalation schedule, while the standard injection schedule reaches 2.4 mg after a longer escalation period. However, the actual cost depends on the price attached to each strength, so this timing difference does not automatically make either option cheaper overall.

Promotions complicate the comparison further. A Wegovy pill may be advertised from £69 or £79 for a new patient, while the normal renewal price is higher. An injection provider may offer a discount code, a reduced starter dose or a multi-month bundle. Comparing only the first visible headline price can therefore produce the wrong conclusion.

The better approach is to compare:

1. the current starting price
2. the price after any promotion ends
3. the expected price at the next dose
4. the maintenance-dose price
5. any subscription or minimum commitment
6. consultation and delivery charges

This gives a more realistic picture of whether the pill or injection is likely to cost less over time.

How Much Could the Pill and Injection Cost Over the First Year?

A full year of private Wegovy pill treatment could cost roughly £1,900–£2,200 or more, while injectable treatment could range from approximately £1,800 to over £3,000, depending on the provider and dose pathway.

Patients comparing Wegovy pill vs injection cost often focus on the monthly price, but the total over six or twelve months may be more useful. Because both formulations increase through several dose levels, a simple calculation such as "£99 multiplied by 12" can significantly underestimate the possible long-term cost.

For the Wegovy pill, an illustrative private-market schedule might use:

• Month 1 at 1.5 mg: around £70–£110

• Month 2 at 4 mg: around £90–£125

• Month 3 at 9 mg: around £115–£145

• Month 4 onward at 25 mg: around £180–£200 or more per month

Using those broad assumptions, a full year of oral treatment could come to roughly £1,900–£2,200 or more. This assumes progression to 25 mg and continued treatment through the year.

For the Wegovy injection, an illustrative schedule might use:

• Month 1 at 0.25 mg: around £75–£150

• Month 2 at 0.5 mg: around £90–£170

• Month 3 at 1 mg: around £105–£200

• Month 4 at 1.7 mg: around £135–£250

• Month 5 onward at 2.4 mg: around £175–£300 or more per month

Using such broad private-market ranges, a year of injected treatment could potentially cost roughly £1,800 to more than £3,000.

These figures are illustrations, not quotes or guarantees. The ranges are intentionally wide because private UK pricing differs substantially. A competitively priced provider can produce a much lower annual total than an expensive service, and temporary promotions can change the first few months.

It is therefore possible for the pill to save money over a year, particularly when compared with an injection provider charging toward the upper end of the market. But it is equally possible for a competitively priced injection service to cost approximately the same as oral treatment.

There are other reasons actual annual costs may differ:

Not everyone reaches the highest dose on the standard timeline. A prescriber may keep a patient at a previous dose level where needed.

Not everyone continues for 12 months. Treatment may be stopped because of side effects, pregnancy planning, changes in clinical circumstances, inadequate response or personal choice.

Provider prices can change. Oral Wegovy is relatively new to the UK market, and competition may move prices in either direction.

Discounts may expire. A low first-month offer can make the beginning of treatment look cheaper than the ongoing plan.

Additional support may be included. Some providers bundle clinical follow-up, delivery or weight-management support into the medicine price, while others structure services differently.

Higher-dose injections change the calculation. For an eligible adult prescribed the newer 7.2 mg once-weekly injection dose, the monthly cost may be higher than at 2.4 mg, depending on the provider.

A realistic cost comparison should therefore use the patient's likely prescribed pathway rather than one generic annual figure.

Is It Worth Switching From Wegovy Injections to the Pill to Save Money?

Switching from the 2.4 mg injection to the 25 mg pill is the only defined UK transition and may reduce costs at some providers, but clinical suitability and the pill's strict fasting requirements must be assessed before any change.

Some patients may consider switching from Wegovy injections to the pill because of cost, particularly if their current private injection service is expensive. However, price alone should not be used to create a self-directed treatment change.

The current UK prescribing information gives one specific transition between the formulations. A patient treated with semaglutide injection 2.4 mg once weekly can be transitioned to semaglutide tablets 25 mg once daily, with the tablets starting one week after the last injection.

That defined transition may make cost comparison particularly relevant for someone already established on 2.4 mg injections. For example, a person paying toward the upper end of private injection pricing could potentially find a 25 mg pill service at a lower monthly price.

However, several cautions matter.

First, the UK prescribing information states that the effect of switching between oral and injected semaglutide cannot easily be predicted because oral absorption is more variable.^[7][3] The pill and injection are not simply interchangeable products selected according to whichever has the lowest monthly price.

Second, the explicit 2.4 mg injection to 25 mg tablet transition should not be generalised to every dose. Someone taking 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 7.2 mg injections should not invent a tablet equivalent.

Third, the daily pill has stricter administration requirements. It should be taken after fasting for at least 8 hours, swallowed whole with a small amount of water, and followed by at least 30 minutes before eating, drinking or taking other oral medicines.^[7][8] A cheaper treatment is not good value if a patient cannot realistically follow the dosing routine.

The weekly injection may be more practical for someone who:

• prefers once-weekly dosing

• eats or drinks immediately after waking

• takes multiple important medicines in the morning

• struggles to remember daily tablets

• is comfortable self-injecting

The pill may be attractive to someone who:

• has significant needle anxiety

• strongly prefers oral treatment

• can follow the fasting requirements consistently

• finds a competitively priced private tablet service

Patients should also compare what each provider includes. A slightly higher price may cover delivery, ongoing clinical support or other services that are charged differently elsewhere.

The same caution applies to claims that pills have fewer hidden costs because they do not require injection pens or needles. From a patient's perspective, many private injection services include the necessary supplies in their advertised treatment price. The relevant question is the actual amount the individual pays, not the theoretical manufacturing cost of the formulation.

In summary, the Wegovy pill can be cheaper than the injection in the UK, but it is not always cheaper. Current private prices overlap substantially. Some providers charge similar amounts for the lower starting stages and similar amounts for the 25 mg pill and 2.4 mg injection, while other providers make the tablet noticeably less expensive than injections.

A sensible comparison should look at the prescribed dose, ongoing monthly price, promotion terms, maintenance costs and what is included in the service. Patients considering a switch should complete a clinical review rather than stopping injections or starting tablets based solely on price.

For many people, the best-value option will be the clinically suitable treatment they can follow consistently at a sustainable long-term cost — not simply whichever product has the cheapest introductory headline.

Scientific References

1. Wegovy 1 mg, FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics.
2. Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics.
3. Wegovy EPAR – Product Information (PDF).
4. Wegovy | European Medicines Agency (EMA).
5. Semaglutide | Drugs – BNF – NICE.
6. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
7. First GLP-1 tablet for weight loss approved in the UK.
8. Rybelsus EPAR – Product Information (PDF).

Frequently Asked Questions